TACE with or without lenvatinib as adjuvant therapy for HCC with microvascular invasion (MVI) or portal vein thrombus (Cheng’s I/II): A single-center, prospective, non-randomized cohort study.
Authors: Chengpei Zhu, Feng Wu, Zibo Xu, Chengjie Li, Liang Di, Xiaofei Zhao, Yang Tan, Shanshan Wang, Kai Liu, Haitao Zhao, Daobing Zeng, Guangming Li